Form 4: Akero Therapeutics Executive Sells Shares to Cover Tax Obligations

Catriona Yale, Chief Development Officer of Akero Therapeutics, sold 723 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 13, 2024, Catriona Yale, the Chief Development Officer of Akero Therapeutics, sold 723 shares of the company's common stock.
• The sale was executed at a price of $28.33 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Yale directly owns 77,692 shares of Akero Therapeutics.
• The sale was automatic under the issuer's 'sell-to-cover' policy and not at the discretion of the reporting person.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sell-to-cover) and doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Executive stock sales are a common occurrence, particularly to cover tax obligations related to equity compensation. The 'sell-to-cover' policy is a standard practice among publicly traded companies.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder perception, but is unlikely to be significant given the reason for the sale.

Key Dates